[Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease].
Glucovance, recently launched by Merck-Lipha (Glucovance 500 mg/2.5 mg and Glucovance 500 mg/5 mg), is a fixed combined therapy of a sulphonylurea (glibenclamide 2.5 or 5 mg) and a biguanide (metformin 500 mg), indicated for the treatment of type 2 diabetes in adult patients. The only current official indication in Belgium is the substitution of a dual therapy with metformin and glibenclamide in patients with a stable and adequate metabolic control. The fixed combination aims at simplifying patient's treatment in order to improve compliance despite polymedication. In addition, it allows targeting synergistically the two main abnormalities of type 2 diabetes, i.e. the insulin secretory defect and the insulin resistance.
Scheen
A J
AJ
Université de Liège, Service de Diabétologie, Nutrition et Maladies métaboliques, Service de Médecine interne générale, Département de Médecine, CHU Sart Tilman.
D015190:Blood Glucose Self-Monitoring; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007333:Insulin Resistance; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology*; D010349:Patient Compliance; D010507:Periodicity
C417231:Glucovance; D007004:Hypoglycemic Agents; D008687:Metformin; D005905:Glyburide